Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.56 |
| ▸ | MAP4K3 | Q8IVH8 | 7/20 | 0.55 |
| ▸ | MET | P08581 | 6/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.55 |
| ▸ | GRK5 | P34947 | 6/20 | 0.52 |
| ▸ | GRK2 | P25098 | 4/20 | 0.52 |
| ▸ | FLT3 | P36888 | 1/20 | 0.52 |
| ▸ | PAK4 | O96013 | 1/20 | 0.50 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.50 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2750611 | 0.90 | MET (0.55) | MAP4K3METKCNH2GRK5GRK2 | |
| SCHEMBL2749285 | 0.90 | GRK5 (0.56) | MAP4K3METKCNH2GRK5GRK2 | |
| SCHEMBL2750035 | 0.90 | MET (0.55) | JAK2MAP4K3METKCNH2GRK5 | |
| SCHEMBL2749711 | 0.87 | MAP4K3 (0.54) | MAP4K3METKCNH2GRK5GRK2 | |
| SCHEMBL2751513 | 0.87 | MAP4K3 (0.58) | JAK2MAP4K3METKCNH2GRK5 | |
| SCHEMBL2748944 | 0.87 | MAP4K3 (0.57) | MAP4K3METKCNH2GRK5GRK2 | |
| SCHEMBL2749789 | 0.86 | MET (0.59) | JAK2MAP4K3METKCNH2GRK5 | |
| SCHEMBL2385920 | 0.85 | MET (0.66) | MAP4K3METKCNH2GRK5GRK2 | |
| SCHEMBL2748628 | 0.85 | MAP4K3 (0.52) | JAK2MAP4K3METKCNH2GRK5 | |
| Hydrochloric Acid SCHEMBL2750062 | 0.85 | MET (0.66) | MAP4K3METKCNH2GRK5GRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090197862-A1 | 2-AMINOPYRIDINE KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. | 2009-08-06 | — | — | US | claimed |
| US-8178668-B2 | 2-aminopyridine kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2012-05-15 | — | — | US | disclosed |
| US-20090197862-A1 | 2-AMINOPYRIDINE KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090197862-A1 | 2-AMINOPYRIDINE KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197862-A1 | 2-AMINOPYRIDINE KINASE INHIBITORS | ERBB2, ABL2, TIE1 | JAK2 57/4885MAP4K3 114/4885MET 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.